Fredag 6 Juni | 20:18:07 Europe / Stockholm

Prenumeration

2025-06-04 12:09:00

According to Saniona’s Q1 2025 report, the company’s current financing is set to support the advancement of its three internal development programs – SAN711, SAN2219, and SAN2355 – toward significant clinical milestones. We reached out to CFO Johnny Stilou for a comment.

Read the full interview at biostock.se:

https://biostock.se/en/2025/06/sanionas-cfo-outlines-clinical-milestone-strategy/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/